EA
IONS icon

Emerald Advisers’s Ionis Pharmaceuticals IONS Stock Holding History

Emerald Advisers’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16,815
Closed -$564K – 286
2021
Q3 		$564K Sell
16,815
-806
-5% -$30.4K 0.02% 186
2021
Q2 		$703K Hold
17,621
– – 0.03% 177
2021
Q1 		$792K Buy
+17,621
New +$983K 0.03% 165
2017
Q4 		– Sell
-22,132
Closed -$1.12M – 254
2017
Q3 		$1.12M Buy
+22,132
New +$1.16M 0.05% 171
2015
Q2 		– Sell
-5,337
Closed -$321K – 348
2015
Q1 		$321K Sell
5,337
-165,732
-97% -$11.2M 0.02% 304
2014
Q4 		$10.6M Sell
171,069
-75,685
-31% -$3.73M 0.56% 59
2014
Q3 		$9.58M Buy
246,754
+47,820
+24% +$1.69M 0.57% 53
2014
Q2 		$6.85M Buy
198,934
+22,498
+13% +$708K 0.39% 90
2014
Q1 		$7.62M Sell
176,436
-145,897
-45% -$7.07M 0.43% 81
2013
Q4 		$12.8M Buy
322,333
+16,388
+5% +$584K 0.7% 43
2013
Q3 		$11.5M Buy
305,945
+33,018
+12% +$986K 0.65% 44
2013
Q2 		$7.33M Buy
+272,927
New +$5.8M 0.45% 75

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Emerald Advisers's IONS Position: Q4 2021 in Review

Emerald Advisers sold out of Ionis Pharmaceuticals (IONS) in Q4 2021, closing a stake of 16,815 shares — an estimated $564K sold.

Emerald Advisers first reported a position in IONS in Q2 2013 and held it in 12 quarters. The position peaked at $12.8M in Q4 2013. 340 funds tracked by Wall St. Rank hold IONS as of Q4 2021.

  • Emerald Advisers reported no remaining Ionis Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Emerald Advisers sold 16,815 Ionis Pharmaceuticals shares in Q4 2021, an estimated $564K.
  • Emerald Advisers first reported a position in Ionis Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Emerald Advisers's Ionis Pharmaceuticals position peaked at $12.8M in Q4 2013.
  • 340 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2021.

Based on Emerald Advisers's 13F filing for Q4 2021, filed 2 Feb 2022.